Sleep disorders are one of the most common acute reactions on the plateau, which can cause serious complications. However, there is no effective and safe treatment currently available. Nimodipine (NMD) is a dihydropyridine calcium channel blocker with neuroprotective and vasodilating activity, mainly used for the treatment of ischemic brain injury. Commercial oral or injectable NMD formulations are not a good option for central neuron diseases due to their poor brain delivery. In this study, nimodipine dissolving microneedles (NDMNs) were prepared for the prevention of sleep disorders caused by hypoxia. NDMNs were composed of NMD and polyvinyl pyrrolidone (PVP) K90 with a conical morphology and high rigidity. After administration of NDMNs on the back neck of mice, the concentration of NMD in the brain was significantly higher than that of oral medication as was confirmed by the fluorescent imaging on mouse models. NDMNs enhanced cognitive function, alleviated oxidative stress, and improved the sleep quality of mice with high-altitude sleep disorders. The blockage of calcium ion overloading may be an important modulation mechanism. NDMNs are a promising and user-friendly formulation for the prevention of high-altitude sleep disorders.
Keyphrases
- sleep quality
- subarachnoid hemorrhage
- brain injury
- cerebral ischemia
- physical activity
- depressive symptoms
- oxidative stress
- drug delivery
- high resolution
- healthcare
- mouse model
- liver failure
- resting state
- white matter
- type diabetes
- quantum dots
- endothelial cells
- adipose tissue
- multiple sclerosis
- functional connectivity
- high fat diet induced
- intensive care unit
- photodynamic therapy
- signaling pathway
- hepatitis b virus
- metabolic syndrome
- mass spectrometry
- diabetic rats
- endoplasmic reticulum stress
- hyaluronic acid
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- wound healing
- heat shock protein
- tissue engineering